• Home
  • News
  • Resignation of the CFO and the succession plan

Captor Therapeutics ®


Resignation of the CFO and the succession plan


Wrocław, June 22, 2021 - Captor Therapeutics S.A. (WSE: CTX) informed that on June 21, 2021 Aleksandra Skibińska resigned from the position of the Member of the Management Board and Chief Financial Officer. Aleksandra Skibińska has agreed to assist the Company to ensure the smooth transition of duties to the new CFO.

 „On behalf of Captor Therapeutics I would like to thank Aleksandra for her great service, insightful input and collaboration in ensuring the continuous growth of the Company over the last 4 years and contributing strongly to the success of our recent IPO. Aleksandra’s departure is an amicable separation by mutual agreement as the Company moves forward into its next phase of developmentsaid Dr Tom Shepherd, CEO and President of the Management Board, Captor Therapeutics.

The process of appointment of the new CFO is nearing completion and the intention of the Company is to finalize this process shortly. The Company will provide timely information on the outcome in accordance with applicable regulations.


About Captor Therapeutics

Captor Therapeutics S.A. is a rapidly growing European biopharmaceutical company with principal operations in Wrocław, Poland. The Company operates in state-of the-art laboratories in the Wrocław Technology Park. Captor is also present in the Swiss Innovation Park, Allschwil, close to Basel, with its subsidiary Captor Therapeutics GmbH.

Captor Therapeutics focuses on the discovery and development of breakthrough drug candidates in diseases with high levels of unmet medical need using Targeted Protein Degradation (TPD). TPD is a revolutionary approach to finding new drugs that can address totally new molecular targets, currently not addressable using classical drugs, as well as improving the treatment options for diseases where existing drugs fail to prove optimal treatment. Captor is conducting, among others, five research and development projects aimed at developing drug candidates for the treatment of undertreated severe conditions, including malignancies and autoimmune diseases.

Captor recently launched a new research and development collaboration with the Japanese company Sosei Heptares combining Captor’s proprietary TPD platform with Sosei Heptares’ expertise and technology in a specific family of drug targets called GPCRs.

TPD technology is a transformational breakthrough because of its potential to target any protein, including proteins considered to be therapeutically un-targetable (undruggable Proteome). Captor Therapeutics is the European leader in TPD technology.

Captor Therapeutics currently has five R&D projects at the preclinical stage (four of which are at the lead optimisation phase).

The Company successfully closed the initial public offering of its shares in April 2021 and is listed on Warsaw Stock Exchange.


More information on Captor Therapeutics is available at: http://www.captortherapeutics.com

LinkedIn: @CaptorTherapeutics

Twitter: @CaptorTherapeu1



For further information, please contact:


Media contact:

Michał Wierzchowski, cc group

telephone +48 531 613 067, email: michal.wievb7qrzchowski@ccgroup.pl